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J. BOUSQUET AND P. CHANEZ 
Service des Maladies Respiratoires, INSERM U&W, Hipita Arnaud de Villeneuve, Montpellier, 
France 
Sputum induction can be used to study airway inflammation in asthmatics. However, it has not been used in patients 
with corticosteroid-dependent asthma requiring long-term oral corticosteroids. The aim of the study was to assess 
the number of eosinophils and the levels of eosinophil cationic protein (ECP) in sputum of 17 corticosteroid- 
dependent asthmatics by comparison with nine mild untreated asthmatics, 10 moderate asthmatics receiving inhaled 
steroids (ICS) and 11 healthy subjects. In the 17 corticosteroid-dependent asthmatics, we examined sputum 
eosinophil markers on two occasions and correlated them with the control of asthma. Eosinophils were undetectable 
in controls and were detected in 63.8% of asthmatics. There were no significant differences between the three groups 
of asthmatics. ECP levels were significantly increased in ICS or corticosteroid-dependent asthmatics by comparison 
to controls and mild asthmatics. There was no significant difference between ICS and corticosteroid-dependent 
asthmatics. During follow-up, corticosteroid-dependent asthmatics with a controlled disease had no significant 
change in eosinophil numbers or ECP levels. On the other hand, corticosteroid-dependent asthmatics with recent 
exacerbations had a non-significant increase in eosinophil numbers and a significant increase in ECP levels. This 
study shows that ECP levels may be more accurate than eosinophil numbers in assessing exacerbations in 
corticosteroid-dependent asthmatics. 
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Introduction 
The natural history of asthma is still poorly characterized 
but a small proportion of asthmatic patients will develop a 
more severe form of the disease, require continuous long- 
term treatment with oral corticosteroids and are referred as 
corticosteroid-dependent asthmatics (l-5). This group is 
heterogeneous as oral corticosteroids are able to control 
asthma in some but not all patients and their best FEV, 
score is highly variable. 
Assessment of airways inflammation in asthma requires 
either invasive techniques using bronchoalveolar lavage 
(BAL) and biopsies or non-invasive techniques such as 
sputum induction (616). Sputum production was found to 
be safe (9) even in severe patients (17). However, no study 
has been carried out to study sputum induction in severe 
corticosteroid-dependent asthmatics. 
The aim of this study was to assess the number of 
eosinophils and the levels of eosinophil cationic protein 
(ECP) in sputum of 17 stable corticosteroid-dependent 
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asthmatics by comparison with nine untreated asthmatics, 
10 asthmatics receiving inhaled steroids and 11 control 
healthy subjects. Moreover, in the 17 corticosteroid- 
dependent patients, we examined eosinophil markers on 
two occasions and attempted to correlate them with the 
control of asthma. 
Materials and Methods 
PATIENT POPULATION 
We studied 36 asthmatic patients ranging in age between 17 
and 65 years (median 47 years). Asthma was defined as 
previously described in detail (18). All patients had a 
reversible airways obstruction characterized by an increase 
of at least 12% in the baseline FEV, value after inhalation 
of 2OOpg of salbutamol and an absolute value of 200 ml 
(19). In all patients, asthma symptoms started before the 
age of 40 years. Patients were excluded if they were current 
smokers or if they had smoked over 10 annual pack-years, 
if they had had a respiratory infection within the month 
preceding the study, or if the FEV, value was under 1 1 due 
to safety reasons. 
Before sputum induction, patients received a step man- 
agement plan depending on the WHO/NHLBI guidelines 
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TABLE 1. Demographic characteristics of the patients 
Controls 
Untreated ICS Corticodependent 
controlled controlled asthmatics 
asthmatics asthmatics at baseline 
Age (years) 30 (27-34) 36 (29-57) 50.5 (38-64) 60 (50-64) 
FEV, (% pred) 106 (96117) 93 (89-98) 80 (72-95) 68 (50-64) 
Treatment (% patients) 
&-agonists pm (% patients) 0 100 100 100 
Inhaled corticosteroids 
% patients 0 0 100 100 
Budesonide median dose kg) 800 1600 (1600-1600) 
Oral corticosteroids 
% patients 0 0 0 100 
Median daily dose of prednisone (annual dose) (mg) 23 (11-38) 
(20) including the control of triggering factors, an 
educational plan for the control of the disease and a 
follow-up based on a daily diary card where they reported 
symptoms, medications and requirement of medical assist- 
ance for exacerbations as well as morning (pre- 
bronchodilator) and evening PEF with a Mini Wright Peak 
Flow Meter (Clement Clark International, London, U.K.). 
The best of three blows was considered. Peak flow 
variability was measured using the WHO/NHLBI guide- 
lines (20). The control of asthma was defined by WHO/ 
NHLBI guidelines (20). Patients were considered to have 
an asthma exacerbation if asthma was not controlled 
for 3 consecutive days. Patients were classified as 
‘uncontrolled’ if they had had an exacerbation within the 
past 15 days preceding sputum induction. Patients were 
classified as ‘controlled’ if they had no exacerbation during 
this period of time. Atopy was defined as previously 
described (18). 
Three groups of asthmatic patients were studied (Table 
1). Nine untreated patients with controlled asthma who had 
not received corticosteroid in any form for at least the past 
3 months, 10 patients with controlled asthma and receiving 
inhaled steroids (budesonide 8OOpg daily), and 17 
corticosteroid-dependent asthmatics with controlled 
asthma. The characteristics of the corticosteroid-dependent 
asthmatics have been previously described (2,3,5). All 
corticosteroid-dependent asthmatics were treated with high 
doses of inhaled corticosteroids (daily dose: 1200-16OOpg 
of budesonide), long acting &-agonists (daily dose: salm- 
eterol IOOpg) and short acting & agonists as required. 
Before starting oral corticosteroids, all of these patients had 
severe asthma for the following reasons. (1) None of these 
patients were considered as having a control of asthma 
symptoms depending on the WHO/NHLBI guidelines (20); 
(2) all of them had peak flow variability; and (3) all 
patients had at least one asthma exacerbation necessitating 
an hospitalization within the past year before oral corticos- 
teroids were started. A daily oral dose of prednisone was 
then added to the previous treatment and the patients were 
then followed for 1 year using the recommendations of the 
WHO/NHLBI guidelines (20). All patients were considered 
as corticosteroid-dependent as the trial to wean them 
from the systemic treatment had always been a failure 
in the past year. Ten of these patients were atopic but only 
one was sensitized to seasonal allergens such as grass 
pollen. 
Eleven healthy subjects aged (22-59 years, median and 
interquartile range: 30, 24.549 years) were used as a 
control group. None of these subjects was a smoker. 
None had had any bronchial infection during the previous 
month. 
The study was approved by the Ethics Committee of the 
University and the patients gave informed consent. 
PROTOCOL OF SPUTUM INDUCTION 
Induced sputum was carried out according to the method of 
Pin et al. (10) and details of the method have recently been 
published in detail (17). Prior to sputum induction, all 
subjects underwent spirometry and then received a dose of 
2OOpg salbutamol by MDI. The sputum induction pro- 
cedure was performed after a second spirometric investiga- 
tion, and spirometry was repeated every 5 min during the 
procedure and immediately after sputum induction was 
completed. The patients were asked to rinse their mouths 
with water before sputum induction to avoid as much as 
possible the salivary contamination of induced sputum 
samples. The hypertonic saline (3, 4 and 5% saline) was 
nebulized with a DPlOO (Syst’Am, France) ultrasonic neb- 
ulizer and was inhaled for 5-min periods for up to 30 min. 
This nebulizer generates particles with a mean mass aero- 
dynamic diameter of 4.5,um, and it has an output of 
2.4 ml min - ‘. Saline concentration was increased every 
10 min. Patients were encouraged to cough throughout the 
procedure and they regularly interrupted inhalation of 
hypertonic saline in order to expectorate sputum into a 
clean plastic container. If troublesome symptoms occurred 
(i.e. wheezing, severe cough or dyspnoea) nebulization was 
discontinued. The nebulization was stopped when a sputum 
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TABLE 2. Results of eosinophils and ECP levels in sputum 
Untreated ICS 
Corticodependent asthmatics 
mild moderate Controlled Controlled Uncontrolled 
Controls asthmatic asthmatics first evaluation follow-up follow-up 
(4 (b) (cl (4 (4 0 
Eosinophils (%) 
CO) (001) (4 co-b, (Od4) (129) 
ECP levels @g 1~ ‘) 13 
(6-17) (1628255) (11?;18) 
165 194 580 
(106313) (153-323) (271-2039) 
Data are medians and interquartile range. 
ICS: inhaled corticosteroids. 
Statistical analysis by Mann-Whitney U-test: eosinophils: P (a/f) <O.OOl; ECP levels: P (a/c) cO.001, 
P (a/d) <O.OOl, P (a/e) <O.OOl; using Bonferroni’s correction only PxO.01 is significant. 
sample was obtained according to the criteria of Pin et al. 
(10). 
EOSINOPHIL COUNTS AND ECP 
MEASUREMENT 
Sputum samples were immediately treated with 10% dithio- 
threitol (Sigma, St Louis, MO, U.S.A.) and centrifuged as 
previously described (21). The volume of the secretion 
sample was measured, then incubated with dithiothreitol 
(DTT, 10’111, Sigma Chemical Co.). The volume of DTT 
used ranged from 100 ~1 to 1 ml according to the volume of 
the sample (l/l v/v). The sample was agitated in a vortex 
mixer for 30 s and the mixture was then drawn in a plastic 
pipette and expelled repeatedly (20 x ) to obtain a fluid 
sample. Phosphate-buffered saline (PBS) was added and the 
sample was mixed using a vortex mixer for another 30 s. 
The supernatants were immediately frozen for subsequent 
analysis. ECP was measured using a commercial radioim- 
munoassay kit (Pharmacia-Upjohn, Uppsala, Sweden). On 
the cell pellet, a cytocentrifugation (Shandon, U.K.) was 
performed and cells enumerated using Dif-Quick. 
STUDY DESIGN 
All the control subjects and asthmatics had a sputum 
induction and markers were measured as described above. 
Patients received a management plan the day of the first 
sputum induction. The follow-up was based on the control 
of asthma defined according to the GINA guidelines (20). 
Then, all corticosteroid-dependent asthmatics were 
followed-up for 3 months and sputum was carried out for a 
second time at 11-13 weeks after the first sputum induction. 
The doses of oral and inhaled corticosteroids were kept 
constant during this follow-up study. 
STATISTICAL ANALYSES 
We used the Wilcoxon W-test for paired data and the 
Mann-Whitney U-test for unpaired data. When multiple 
data were analysed, Bonferroni’s correction was used. 
Results are given as medians and interquartile range. 
Results 
TOLERANCE OF SPUTUM 
In all subjects, sputum induction was well tolerated and we 
did not stop the procedure before obtaining satisfactory 
sputum. 
SPUTUM EOSINOPHJL COUNTS AND ECP 
LEVELS 
Sputum eosinophils were undetectable in control subjects. 
They were found in increased numbers in the three groups 
of asthmatic patients (Table 2, Fig. 1). Sputum ECP 
levels were detectable in all subjects tested. They were also 
found to be increased in the three groups of asthmatic 
patients (Table 2 and Fig. 2). There was a significant 
increase in ECP levels in asthmatics by comparison to 
controls. 
SPUTUM EOSINOPHIL COUNTS AND ECP 
LEVELS DURING FOLLOW-UP OF 
CORTICOSTEROID-DEPENDENT ASTHMATICS 
In the 10 corticosteroid-dependent asthmatics who had 
controlled disease throughout the study, eosinophil counts 
and ECP levels remained stable (Fig. 3). On the other hand, 
in patients who had a recent exacerbation of asthma (within 
the past 2 weeks), ECP levels significantly increased 
(PcO.02, Wilcoxon W-test) but eosinophil counts did not 
vary significantly (Fig. 4). In uncontrolled corticosteroid- 
dependent asthmatics, there was a significant increase in 
ECP levels in comparison to other asthmatic groups 
(Table 2). 
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FIG. 1. Eosinophil percentages in sputum at baseline. 
ICS: Moderate asthmatics treated with inhaled steroids; 
OSC: severe corticosteroid-dependent asthmatics treated 
with oral steroids; shaded area: undetectable eosinophils. 
Discussion 
In this study, we showed that ECP levels appear to be more 
profoundly increased than eosinophil counts in sputum of 
asthmatics and that ECP levels may be a better predictor of 
exacerbations than eosinophil counts. 
We have confirmed the safety of sputum induction (17) in 
patients with severe asthma, even though some of them had 
uncontrolled disease. 
Several sputum induction studies (14,16,22-25) and naive 
sputum studies (2628) have examined eosinophil numbers 
and ECP levels in asthmatics. Differences in results are not 
related to the method of sputum analysis (29). There is no 
general consensus as some studies found that cell counts 
were more accurate than ECP levels and others found the 
opposite result. In the present study, we observed that ECP 
levels are detectable in the sputum of all subjects, whereas 
only 63.8% of asthmatics had sputum eosinophils. Median 
levels of sputum ECP are increased in the asthmatic groups 
in the present study, as reported previously. However, this 
study is original since patients with more severe 
corticosteroid-dependent asthma have been studied. As in 
many previous studies, eosinophil counts or ECP levels do 
not differentiate clearly the severity of the disease probably 
because many or most patients were receiving inhaled 
corticosteroids (8,24,28). Inhaled corticosteroids have anti- 
inflammatory properties since they were shown to reduce 
eosinophil numbers and ECP levels in the BAL fluid and 
sputum (30,31). However, in many studies, eosinophilic 
inflammation is not completely abolished in the airways by 
11 I I I I 
Controls Mild ICS 
untreated Co%iled 
Asthmatics 
FIG. 2. ECP levels in sputum at baseline. ICS: Moderate 
asthmatics treated with inhaled steroids; OSC: severe 
corticosteroid-dependent asthmatics treated with oral 
steroids. 
inhaled corticosteroids even though the patients appear to 
have clinically controlled disease. This is the case in the 
present study and such data may explain why the clinical 
benefits of inhaled corticosteroids may not last very long 
after the treatment is stopped. Moreover, in the present 
study it has been observed that asthmatics receiving inhaled 
steroids and controlled corticosteroid-dependent asthmatics 
have similar levels of ECP and numbers of eosinophils in 
sputum. However, these results in corticosteroid-dependent 
asthmatics may be surprising since as eosinophils are not 
usually found in the bronchial mucosa of corticosteroid- 
dependent asthmatics [Chanez et al. (4) unpublished data] 
The reasons explaining the presence of eosinophils in 
sputum of these patients are unknown, 
Other markers of airway inflammation can be studied, in 
particular since it has been shown that corticosteroid- 
dependent asthma is often associated with airway neu- 
trophilia (4) and that there is an increase in sputum 
neutrophil markers in asthmatics (32,33). However, here we 
studied only eosinophil markers. 
The definition of asthma control and exacerbations is still 
a matter of debate. However, we used the WHO/NHLBI 
guidelines (20) to assess the control of asthma and exacer- 
bations were characterized by uncontrolled asthma for a 
sufficient length of time, as proposed (34). The greatest 
increase in eosinophils and ECP levels was observed 
in uncontrolled corticosteroid-dependent asthmatics. 
Corticosteroid-dependent asthmatics with stable disease 
had similar ECP level and eosinophil numbers in sputum 
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FIG. 3. Evolution of eosinophils in sputum measured at a 3-month interval in corticosteroid-dependent asthma. (a) Con- 
trolled asthma; (b) uncontrolled asthma; both not significant (Wilcoxon W-test). 
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FIG. 4. Evolution of ECP levels in sputum measured at a 3-month interval in corticosteroid-dependent asthma. (a) Con- 
trolled asthma (ns., Wilcoxon W-test); (b) uncontrolled asthma (PcO.02, Wilcoxon W-test). 
during the two examinations. Only ECP levels were found that inhaled and oral corticosteroids cannot block eosino- 
to be increased after exacerbations. These findings accord phi1 activation during an asthma exacerbation in such 
with biopsy (35) or sputum studies (36,37) carried out severe patients. Further studies are, however, required to 
during asthma exacerbations and showing eosinophilic assess whether eosinophil markers are predictive of an 
inflammation. Moreover, we have shown for the first time exacerbation. 
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